Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

• Conflicting data exist regarding the prognostic and predictive impact of survivin (BIRC5) in breast cancer. We previously reported survivin cytoplasmic-to-nuclear ratio (CNR) as an independent prognostic indicator in breast cancer. Here, we validate survivin CNR in a separate and extended cohort. Furthermore, we present new data suggesting that a low CNR may predict outcome in tamoxifen-treated patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Adult

Aged

Aged

80 and over

Algorithms

Breast Neoplasms

chemistry

mortality

therapy

Cell Nucleus

chemistry

Chi-Square Distribution

Cytoplasm

chemistry

Decision Trees

Estrogen Receptor Modulators

therapeutic use

Female

Humans

Image Interpretation

Computer-Assisted

Immunohistochemistry

Inhibitor of Apoptosis Proteins

Kaplan-Meier Estimate

Ki-67 Antigen

analysis

Microtubule-Associated Proteins

analysis

Middle Aged

Pattern Recognition

Automated

Predictive Value of Tests

Proportional Hazards Models

Receptor

erbB-2

analysis

Receptors

Estrogen

analysis

Receptors

Progesterone

analysis

Reproducibility of Results

Risk Assessment

Risk Factors

Sweden

Tamoxifen

therapeutic use

Time Factors

Tissue Array Analysis

Treatment Outcome

Tumor Markers

Biological

analysis

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)